A weekly tirzepatide pen that acts on two appetite hormones, GLP-1 and GIP. It’s approved in Japan for type 2 diabetes, so for weight loss it’s off-label use. A doctor decides whether it suits you.
Reviewed by our doctors · Updated
Your first month: four weekly pens at 2.5mg, a low starting dose so your body can adjust.
Illustration only, at the fastest pace. Your doctor sets each step.
Tirzepatide acts like two gut hormones, GLP-1 and GIP, that help regulate appetite. In clinical trials, weight loss was reported when it was paired with diet and exercise. Results vary.
Your doctor recommends what fits, and you can change it later.
Prescription only: a free video consult with a doctor licensed in Japan comes first, and the doctor may decide not to prescribe. Private care (jiyū shinryō): not covered by public health insurance. Prices include tax. For illustration: your medicine may look different. Mounjaro, Rybelsus and Victoza: Approved in Japan for type 2 diabetes. Prescribing it for weight loss is off-label use. Japan’s Relief System for Sufferers from Adverse Drug Reactions doesn’t cover off-label use. Wegovy is approved in Japan for obesity disease.
All online, no clinic visits. Screens are for illustration.
A few questions about your health, your weight and any medicine you take. Only your doctor sees them.
A doctor licensed in Japan checks treatment suits you and explains how to use the pen. Photo ID is required by law.
Your doctor checks in and decides whether, and when, to raise your dose.
A prescription is day one. We’re in it for every day after.

Three weeks in a row. How’s your stomach been? Let’s talk about your next step before week 5.
Mounjaro is approved in Japan for type 2 diabetes, not for weight loss. Before anything is prescribed, your doctor explains what off-label use means for you, including the risks.
A few questions to see if you’re eligible, then a video consult.